About Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MYOV
CUSIPN/A
Phone203-318-9709
Debt
Debt-to-Equity Ratio0.35%
Current Ratio5.04%
Quick Ratio5.04%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book7.48
Profitability
EPS (Most Recent Fiscal Year)($1.70)
Net Income$-83,440,000.00
Net MarginsN/A
Return on Equity-90.86%
Return on Assets-74.94%
Miscellaneous
Employees36
Outstanding Shares60,990,000
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
How were Myovant Sciences' earnings last quarter?
Myovant Sciences (NYSE:MYOV) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.28. View Myovant Sciences' Earnings History.
When is Myovant Sciences' next earnings date?
What price target have analysts set for MYOV?
5 brokers have issued 12 month price targets for Myovant Sciences' shares. Their predictions range from $18.00 to $25.00. On average, they anticipate Myovant Sciences' stock price to reach $21.00 in the next year. View Analyst Ratings for Myovant Sciences.
What are Wall Street analysts saying about Myovant Sciences stock?
Here are some recent quotes from research analysts about Myovant Sciences stock:
- 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (4/18/2018)
- 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), AnaptysBio (ANAB), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), Motif (MTFB), Intercept Pharmaceuticals (ICPT) and Corcept Therapeutics (CORT).
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Dr. Lynn Seely, Chief Exec. Officer, Pres and Exec. Director (Age 59)
- Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)
- Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)
- Ms. Julie Tran MBA, MSHR, Exec. Director of HR
- Mr. Bryan Selby, Sr. VP of Product Devel.
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Has Myovant Sciences been receiving favorable news coverage?
Headlines about MYOV stock have trended somewhat positive on Friday, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Myovant Sciences earned a media sentiment score of 0.09 on Accern's scale. They also gave headlines about the company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Myovant Sciences?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of MYOV stock can currently be purchased for approximately $20.73.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $1.37 billion. The company earns $-83,440,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (MYOV)
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Myovant Sciences (NYSE:MYOV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Myovant Sciences (NYSE MYOV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 81.44%
Myovant Sciences (NYSE MYOV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Holdings Ltd. Dexxon | Major Shareholder | Buy | 1,110,015 | $20.27 | $22,500,004.05 | |  |
| 3/19/2018 | Pharmaceuticals Interna Takeda | Major Shareholder | Buy | 7,420,625 | $18.67 | $138,543,068.75 | | |
(Data available from 1/1/2013 forward)
Myovant Sciences (NYSE MYOV) News Headlines
| Source: |
|
Myovant Sciences (NYSE:MYOV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Myovant Sciences (NYSE:MYOV) Income Statement, Balance Sheet and Cash Flow Statement
Myovant Sciences (NYSE MYOV) Stock Chart for Friday, April, 20, 2018
Loading chart…
